<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Adagene Inc (NASDAQ: ADAG) has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The agreement includes an open-label, dose-escalation, and expansion clinical study of ADG106 combined with Merck’s Keytruda (pembrolizumab) in advanced or metastatic solid and/or hematological malignancies.
...read full article on Benzinga